Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14898394 | 0.86 | ALOX15 (0.36) | KDM4EMAPK1HIF1APAOX | |
| SCHEMBL19686889 | 0.86 | ALOX15 (0.36) | KDM4EMAPK1HIF1APAOX | |
| SCHEMBL25908987 | 0.81 | ALOX15 (0.38) | KDM4EMAPK1HIF1APAOXMAOA | |
| SCHEMBL20878389 | 0.77 | — | — | |
| SCHEMBL25908989 | 0.77 | KDM1A (0.50) | — | |
| SCHEMBL13046403 | 0.77 | MAOA (0.36) | KDM4EMAPK1HIF1APAOXMAOA | |
| SCHEMBL23707811 | 0.76 | KISS1R (0.38) | KDM4EMAPK1HIF1A | |
| SCHEMBL21678029 | 0.75 | GRM4 (0.35) | KDM4EMAPK1HIF1APAOXMAOA | |
| SCHEMBL14950911 | 0.75 | CES1 (0.38) | — | |
| SCHEMBL17131053 | 0.73 | ACLY (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | VenatoRx Pharmaceuticals, Inc. (US) | 2023-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | SLC29A2, SLC29A1, PNP | KDM4E 3750/4885MAPK1 4374/4885HIF1A 2851/4885 |
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | SLC29A2, SLC29A1, PNP | KDM4E 3750/4885MAPK1 4374/4885HIF1A 2851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.